{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:57:12Z","timestamp":1794412632954,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:00:00Z","timestamp":1395446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2334-14-158","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T10:01:53Z","timestamp":1395482513000},"source":"Crossref","is-referenced-by-count":15,"title":["Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia"],"prefix":"10.1186","volume":"14","author":[{"given":"Andargachew","family":"Mulu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe Gerd","family":"Liebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,22]]},"reference":[{"key":"3084_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","volume":"367","author":"P Braitstein","year":"2006","unstructured":"Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, ART-LINC Collaboration, ART-CC groups: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006, 367: 817-824.","journal-title":"Lancet"},{"key":"3084_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1086\/427212","volume":"40","author":"RM Novak","year":"2005","unstructured":"Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M, Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected treatment na\u00efve patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005, 40: 468-474. 10.1086\/427212.","journal-title":"Clin Infect Dis"},{"key":"3084_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.aids.0000196172.35056.b7","volume":"20","author":"D Pillay","year":"2006","unstructured":"Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, K\u00fccherer C, Poggensee G, Gill J, Porter K, CASCADE Virology Collaboration: The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006, 20: 21-28.","journal-title":"AIDS"},{"key":"3084_CR4","first-page":"17","volume":"14","author":"E Frentz","year":"2012","unstructured":"Frentz E, Boucher CAB, Vijver D: Temporal changes in the epidemiology of transmission of drug resistance HIV-1 across the world. AIDS Rev. 2012, 14: 17-27.","journal-title":"AIDS Rev"},{"issue":"10","key":"3084_CR5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1086\/644505","volume":"200","author":"J Vercauteren","year":"2009","unstructured":"Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, K\u00fccherer C, Struck D, Schmit JC, Asj\u00f6 B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poliak M, Puchhammer-St\u00f6ckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, et al: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009, 200 (10): 1503-1508. 10.1086\/644505. doi:10.1086\/644505","journal-title":"J Infect Dis"},{"key":"3084_CR6","first-page":"61038","volume":"6736","author":"RK Gupta","year":"2012","unstructured":"Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S: Global trends in antiretroviral resistance in treatment-na\u00efve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012, 6736: 61038-61041.","journal-title":"Lancet"},{"key":"3084_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/aid.2006.0270","volume":"23","author":"A Kassu","year":"2007","unstructured":"Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiura W: Molecular epidemiology of HIV-1 in treatment naive patients in North Ethiopia. AIDS Res Hum Retroviruses. 2007, 23: 564-568. 10.1089\/aid.2006.0270.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 2","key":"3084_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","volume":"13","author":"WE Abegaz","year":"2008","unstructured":"Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K, Wuhib T, Ismael S, Nkengasong J, Mekonen T, Berhanu H, Messele T, Lulseged S, Maayan S, Mengistu Y: Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther. 2008, 13 (Suppl 2): 89-94.","journal-title":"Antivir Ther"},{"key":"3084_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/QAD.0b013e328342ff93","volume":"25","author":"J Hemelaar","year":"2011","unstructured":"Hemelaar J, Gouwsb E, Ghysb DP, WHO-UNAIDS Network for HIV isolation and characterization: Global trends in molecular epidemiology of HIV-1 during 2000\u20132007. AIDS. 2011, 25: 679-689. 10.1097\/QAD.0b013e328342ff93.","journal-title":"AIDS"},{"key":"3084_CR10","first-page":"83","volume":"14","author":"WR Lihana","year":"2012","unstructured":"Lihana WR, Ssemwanga D, Abimiku A, Ndimbi A: Update on HIV-1 diversity in Africa: A decade in review. AIDS Rev. 2012, 14: 83-100.","journal-title":"AIDS Rev"},{"key":"3084_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMra1004180","volume":"365","author":"MA Wainberg","year":"2011","unstructured":"Wainberg MA, Zaharatos GA, Brenner BG: Mechanisms of disease development of antiretroviral drug resistance. N Engl J Med. 2011, 365: 37-46. 10.1056\/NEJMicm1104783.","journal-title":"N Engl J Med"},{"key":"3084_CR12","volume-title":"Interim WHO clinical staging of HIV\/AIDS & HIV\/AIDS case definitions for surveillance: African region","author":"World Health Organization","year":"2005","unstructured":"World Health Organization: Interim WHO clinical staging of HIV\/AIDS & HIV\/AIDS case definitions for surveillance: African region. 2005, Switzerland: World Health Organization, http:\/\/www.who.int\/hiv\/pub\/guidelines\/clinicalstaging.pdf ,"},{"issue":"1","key":"3084_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2334-14-28","volume":"14","author":"A Mulu","year":"2014","unstructured":"Mulu A, Liebert UG, Maier M: Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014, 14 (1): 28-10.1186\/1471-2334-14-28. doi:10.1186\/1471-2334-14-28","journal-title":"BMC Infect Dis"},{"key":"3084_CR14","volume-title":"Geneious v5.4","author":"AJ Drummond","year":"2011","unstructured":"Drummond AJ, Ashton B, Buxton S, Cheung M, Cooper A, Duran C, Field M, Heled J, Kearse M, Markowitz S, Moir R, Stones-Havas S, Sturrock S, Thierer T, Wilson A: Geneious v5.4. 2011, http:\/\/www.geneious.com ,"},{"key":"3084_CR15","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/molbev\/msr121","volume":"28","author":"K Tamura","year":"2011","unstructured":"Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: Molecular evolutionary genetics analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol. 2011, 28: 2731-2739. 10.1093\/molbev\/msr121.","journal-title":"Mol Biol Evol"},{"key":"3084_CR16","first-page":"6","volume":"21","author":"AV Johnson","year":"2013","unstructured":"Johnson AV, Calvez V, G\u00fcnthard HF, Paredes R, Pillay D, Shater R, Wensing AM, Richman DD: Update of the drug resistance mutations in HIV-1: International AIDS Society-USA. Top HIV Med. 2013, 21: 6-14.","journal-title":"Top HIV Med"},{"key":"3084_CR17","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1371\/journal.pmed.0020112","volume":"2","author":"R Kantor","year":"2005","unstructured":"Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, et al: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med. 2005, 2: e112-10.1371\/journal.pmed.0020112. doi:10.1371\/journal.pmed.0020112","journal-title":"PLoS Med"},{"key":"3084_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2217\/hiv.09.30","volume":"3","author":"CA Philip","year":"2009","unstructured":"Philip CA, Kantor R: Transmitted drug resistance in non-subtype B HIV-1 infection. HIV Ther. 2009, 3: 447-465. 10.2217\/hiv.09.30.","journal-title":"HIV Ther"},{"key":"3084_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1758-2652-12-11","volume":"12","author":"JL Martinez-Cajas","year":"2009","unstructured":"Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA: Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996\u20132008). J Int AIDS Coc. 2009, 12: 11-19. 10.1186\/1758-2652-12-11.","journal-title":"J Int AIDS Coc"},{"key":"3084_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","volume":"21","author":"RW Shafer","year":"2007","unstructured":"Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007, 21: 215-223. 10.1097\/QAD.0b013e328011e691.","journal-title":"AIDS"},{"key":"3084_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1471-2458-11-422","volume":"11","author":"Y Dessie","year":"2011","unstructured":"Dessie Y, Gerbaba M, Bedru A, Davey G: Risky sexual practice and related factors among ART attendees in Addis Ababa public hospital Ethiopia: a cross-sectional study. BMC Public Health. 2011, 11: 422-10.1186\/1471-2458-11-422. doi:10.1186\/1471-2458-11-422","journal-title":"BMC Public Health"},{"key":"3084_CR22","unstructured":"World Health Organization HIVDR status report. http:\/\/www.who.int\/hiv\/topics\/drugresistance\/status\/en\/index.html ,"},{"key":"3084_CR23","doi-asserted-by":"publisher","first-page":"e23091","DOI":"10.1371\/journal.pone.0023091","volume":"6","author":"C Kasang","year":"2011","unstructured":"Kasang C, Kalluvya S, Majinge C, Stich A, Bodem J, Kongola G, Jacobs GB, Mlewa M, Mildner M, Hensel I, Horn A, Preiser W, van Zyl G, Klinker H, Koutsilieri E, Rethwilm A, Scheller C, Weissbrich B: HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO Threshold HIVDR Survey is dramatically high. PLoS One. 2011, 6: e23091-10.1371\/journal.pone.0023091. doi:10.1371\/journal.pone.0023091","journal-title":"PLoS One"},{"key":"3084_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1371\/journal.pmed.0050158","volume":"5","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na\u00efve populations and associate with reduced treatment efficacy. PLoS Med. 2008, 5: 158-165. 10.1371\/journal.pmed.0050158. doi:10.1371\/journal.pmed.0050158","journal-title":"PLoS Med"},{"key":"3084_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1086\/587660","volume":"46","author":"\u00c9 Waters","year":"2008","unstructured":"Waters \u00c9, Nelson M, Mandalia S, Bowe M, Powles T, Gazzard B, Stebbing J: The risks and incidence of K65R and L74V mutations and subsequent virologic response. Clin Infect Dis. 2008, 46: 96-100. 10.1086\/523001.","journal-title":"Clin Infect Dis"},{"key":"3084_CR26","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1086\/498069","volume":"192","author":"JE Gallant","year":"2005","unstructured":"Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study: Early virologic non-response to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005, 192: 1921-1930. 10.1086\/498069.","journal-title":"J Infect Dis"},{"key":"3084_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1089\/aid.2008.0180","volume":"24","author":"V Pillay","year":"2008","unstructured":"Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L: HIV type 1 subtypes C drug resistance among paediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008, 24: 1449-1454. 10.1089\/aid.2008.0180.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3084_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/QAI.0b013e3181b06125","volume":"52","author":"CA Hawkins","year":"2009","unstructured":"Hawkins CA, Chaplin B, Idoko J, Ekong E, Adewole I, Gashau W, Murphy RL, Kanki P, APIN Plus\/Harvard PEPFAR Team: 2009: Clinical and genotypic findings in HIV infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr. 2009, 52: 228-234. 10.1097\/QAI.0b013e3181b06125.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3084_CR29","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jmv.21567","volume":"81","author":"D Turner","year":"2009","unstructured":"Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G, Pollack S, Kessner R, Wainberg MA, Avidor B: Prevalence of the K65R Resistance Reverse Transcriptase Mutation in Different HIV-1 Subtypes in Israel. J Med Virol. 2009, 81: 1509-1512. 10.1002\/jmv.21567.","journal-title":"J Med Virol"},{"key":"3084_CR30","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.1128\/JVI.00712-06","volume":"80","author":"JD Baxter","year":"2006","unstructured":"Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL: Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol. 2006, 80: 10794-10801. 10.1128\/JVI.00712-06.","journal-title":"J Virol"},{"key":"3084_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jcv.2004.03.015","volume":"31","author":"A Holguin","year":"2004","unstructured":"Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol. 2004, 31: 215-220. 10.1016\/j.jcv.2004.03.015.","journal-title":"J Clin Virol"},{"key":"3084_CR32","first-page":"256982","volume-title":"Mol Biol Int","author":"MA Wainberg","year":"2012","unstructured":"Wainberg MA, Brenner BG: The Impact of HIV Genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int. 2012, 256982-doi:10.1155\/2012\/256982"},{"key":"3084_CR33","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1056\/NEJMra0706737","volume":"358","author":"BS Taylor","year":"2008","unstructured":"Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM: The challenge of HIV-1 subtype diversity. N Engl J Med. 2008, 358: 1590-1602. 10.1056\/NEJMra0706737. doi:10.1056\/NEJMra0706737","journal-title":"N Engl J Med"},{"key":"3084_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jcv.2006.05.001","volume":"36","author":"A Holguin","year":"2008","unstructured":"Holguin A, Sune C, Hamy F, Soriano V, Klimkait T: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2008, 36: 264-270.","journal-title":"J Clin Virol"},{"key":"3084_CR35","first-page":"179","volume":"26","author":"E Tsega","year":"1988","unstructured":"Tsega E, Mengesha B, Nordenf\u00eart E, Hansson BG, Lindberg J: Serologically survey of human immunodeficiency virus infection in Ethiopia. Ethiop Med J. 1988, 26: 179-184.","journal-title":"Ethiop Med J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-14-158\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:08:06Z","timestamp":1689077286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-14-158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,22]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3084"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-14-158","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,22]]},"article-number":"158"}}